Kaken Pharmaceutical Co., Ltd. (4521) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Suzuken Co., Ltd.

Nippon Shinyaku Co., Ltd.

Tsumura & Co.

Sumitomo Pharma Co., Ltd.

Santen Pharmaceutical Co., Ltd.

SAWAI GROUP HOLDINGS Co., Ltd.

Hisamitsu Pharmaceutical Co., Inc.

Kaken Pharmaceutical Co., Ltd.

JCR Pharmaceuticals Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

Why is Kaken Pharmaceutical Co., Ltd. ?

Weak Long Term Fundamental Strength with a -172.57% CAGR growth in Operating Profits over the last 5 years

Poor long term growth as Net Sales has grown by an annual rate of -0.13% and Operating profit at -172.57% over the last 5 years

Underperformed the market in the last 1 year

The stock has generated a return of 3.07% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 60.14%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Kaken Pharmaceutical Co., Ltd. for you?

Low Risk, High Return

Absolute

Risk Adjusted

Volatility

Kaken Pharmaceutical Co., Ltd.

3.07%

1210.50

18.59%

Japan Nikkei 225

60.14%

2.05

29.37%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-0.13%

EBIT Growth (5y)

-172.57%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.43

Sales to Capital Employed (avg)

0.54

Tax Ratio

7.26%

Dividend Payout Ratio

335.97%

Pledged Shares

Institutional Holding

0.10%

ROCE (avg)

14.71%

ROE (avg)

8.17%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.14

EV to EBIT

-32.49

EV to EBITDA

-139.17

EV to Capital Employed

1.20

EV to Sales

1.64

PEG Ratio

Dividend Yield

ROCE (Latest)

-3.69%

ROE (Latest)

-1.26%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

28What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -33.57% (YoY

NET SALES(Q)

Highest at JPY 30,154 MM

OPERATING PROFIT(Q)

Highest at JPY 11,903 MM

OPERATING PROFIT MARGIN(Q)

Highest at 39.47 %

PRE-TAX PROFIT(Q)

Highest at JPY 11,244 MM

NET PROFIT(Q)

Highest at JPY 8,440.5 MM

EPS(Q)

Highest at JPY 222.85

-10What is not working for the Company

CASH AND EQV(HY)

Lowest at JPY 108,848 MM

INTEREST(Q)

Highest at JPY 14 MM

Here's what is working for Kaken Pharmaceutical Co., Ltd.

Pre-Tax Profit

At JPY 11,244 MM has Grown at 2,655.88%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (JPY MM)

Net Profit

At JPY 8,440.5 MM has Grown at 3,022.24%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (JPY MM)

Net Sales

At JPY 30,154 MM has Grown at 59.82%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (JPY MM)

Net Sales

Highest at JPY 30,154 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Operating Profit

Highest at JPY 11,903 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (JPY MM)

Operating Profit Margin

Highest at 39.47 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at JPY 11,244 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (JPY MM)

Net Profit

Highest at JPY 8,440.5 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (JPY MM)

EPS

Highest at JPY 222.85

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (JPY)

Raw Material Cost

Fallen by -33.57% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Kaken Pharmaceutical Co., Ltd.

Interest

Highest at JPY 14 MM

in the last five periods and Increased by 7.69% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Cash and Eqv

Lowest at JPY 108,848 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents